Friday, June 27, 2025 6/27/2025

AN ADENOVIRAL-BASED MUCOSAL VACCINE FOR AIDS

Award Number: R21DE016323
ORGANIZATION: NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 04/01/2004
PERIOD OF PERFORMANCE END DATE: 03/31/2006

Group Awards By:

View Award Description

AN ADENOVIRAL-BASED MUCOSAL VACCINE FOR AIDS - DESCRIPTION (provided by applicant): AIDS is a worldwide health problem with 36 million people infected with HIV and estimated 5 million new infections occurring per year. These numbers indicate the need for a prophylactic vaccine to prevent the further spread of the disease. Despite tremendous efforts in AIDS vaccine research, traditional methods of vaccine development have failed to produce an effective vaccine for HIV infection. Recent vaccine efforts have focused on eliciting cellular immune responses directed against structural proteins of HIV instead/in addition to targeting humoral immune responses to the envelope. With that approach, adenoviral vector based vaccines have shown a great potential as vaccines for HIV in humans. Adenoviral vectors elicit strong innate immune responses, which greatly aid in inducing strong cellular immune responses. Moreover, adenoviruses are excellent as mucosal vaccines. However, one major drawback of adenoviral vaccines is prior immunity to adenoviruses in human, which could limit their efficacy. We propose to utilize a PEGylation technique to mask our Adeno-based AIDS vaccine vector, Ad/HIV, and test its efficacy in vivo. We propose to evaluate innate immune responses induced by the mucosal administration of PEGylated Ad/HIV (via intranasal route) and cellular immune responses (CTL and cytokine profiles) directed to HIV immunogen; gag encoded by the adenovector. In addition, we will determine both systemic and mucosal immune responses generated to PEGylated Ad/HIV. We will test the efficacy of PEGylated Ad/HIV both in naive mice and in mice with pre-existing immunity to adenoviruses. The results from this study will provide the groundwork for the development of a highly effective mucosal AIDS vaccine that can be repeatedly administered to patients with high efficacy.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2005 ( Subtotal = $293,250 )
2005	2005	LA JOLLA INSTITUTE FOR MOLECULAR MEDICINE	4570 EXECUTIVE DR, SUITE 100	SAN DIEGO	CA	92121	SAN DIEGO	USA	Oral Diseases and Disorders Research	000	2	3/31/2005	NON-COMPETING CONTINUATION	$293,250
														Subtotal = $293,250

Issue Date FY: 2004 ( Subtotal = $293,250 )
2004	2004	LA JOLLA INSTITUTE FOR MOLECULAR MEDICINE	4570 EXECUTIVE DR, SUITE 100	SAN DIEGO	CA	92121	SAN DIEGO	USA	Oral Diseases and Disorders Research	000	1	3/19/2004	NEW	$293,250
														Subtotal = $293,250

Grand Total All Awards = $586,500

Top

All Categories

About

Search

Reports

Data Submission

Award Information

AN ADENOVIRAL-BASED MUCOSAL VACCINE FOR AIDS

Award Number: R21DE016323

ORGANIZATION: NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 04/01/2004

PERIOD OF PERFORMANCE END DATE: 03/31/2006

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer